Shelton Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $356K | Sell |
6,219
-187
| -3% | -$10.2K | 0.01% | 477 |
|
|
2026
Q1 | $362K | Hold |
6,406
| – | – | 0.01% | 453 |
|
|
2025
Q4 | $381K | Buy |
+6,406
| New | +$349K | 0.01% | 425 |
|
|
2025
Q3 | – | Sell |
-6,760
| Closed | -$372K | – | 729 |
|
|
2025
Q2 | $372K | Sell |
6,760
-114
| -2% | -$6.71K | 0.01% | 423 |
|
|
2025
Q1 | $486K | Sell |
6,874
-311
| -4% | -$20.9K | 0.01% | 338 |
|
|
2024
Q4 | $472K | Sell |
7,185
-268
| -4% | -$18K | 0.01% | 361 |
|
|
2024
Q3 | $524K | Sell |
7,453
-148
| -2% | -$12.4K | 0.01% | 338 |
|
|
2024
Q2 | $626K | Buy |
+7,601
| New | +$633K | 0.02% | 307 |
|
|
2020
Q4 | – | Sell |
-13,199
| Closed | -$1M | – | 741 |
|
|
2020
Q3 | $1M | Hold |
13,199
| – | – | 0.04% | 347 |
|
|
2020
Q2 | $1.63M | Hold |
13,199
| – | – | 0.09% | 200 |
|
|
2020
Q1 | $1.11M | Sell |
13,199
-210
| -2% | -$18.1K | 0.08% | 207 |
|
|
2019
Q4 | $1.13M | Sell |
13,409
-1,900
| -12% | -$144K | 0.06% | 228 |
|
|
2019
Q3 | $1.03M | Hold |
15,309
| – | – | 0.06% | 222 |
|
|
2019
Q2 | $1.31M | Buy |
15,309
+13,949
| +1,026% | +$1.19M | 0.08% | 209 |
|
|
2019
Q1 | $15.3K | Sell |
1,360
-13,949
| -91% | -$1.29M | 0.06% | 270 |
|
|
2018
Q4 | $1.3M | Hold |
15,309
| – | – | 0.09% | 190 |
|
|
2018
Q3 | $1.49M | Hold |
15,309
| – | – | 0.08% | 198 |
|
|
2018
Q2 | $1.44M | Buy |
15,309
+3,092
| +25% | +$271K | 0.09% | 194 |
|
|
2018
Q1 | $990K | Hold |
12,217
| – | – | 0.06% | 233 |
|
|
2017
Q4 | $1.09M | Hold |
12,217
| – | – | 0.07% | 222 |
|
|
2017
Q3 | $1.14M | Hold |
12,217
| – | – | 0.08% | 214 |
|
|
2017
Q2 | $1.11M | Buy |
12,217
+1,591
| +15% | +$145K | 0.08% | 218 |
|
|
2017
Q1 | $933K | Buy |
10,626
+1,677
| +19% | +$149K | 0.06% | 235 |
|
|
2016
Q4 | $741K | Hold |
8,949
| – | – | 0.06% | 278 |
|
|
2016
Q3 | $828K | Hold |
8,949
| – | – | 0.07% | 243 |
|
|
2016
Q2 | $696K | Sell |
8,949
-2,950
| -25% | -$251K | 0.06% | 282 |
|
|
2016
Q1 | $981K | Buy |
11,899
+1,021
| +9% | +$83.1K | 0.09% | 202 |
|
|
2015
Q4 | $1.14M | Buy |
10,878
+2,908
| +36% | +$304K | 0.11% | 179 |
|
|
2015
Q3 | $839K | Buy |
+7,970
| New | +$1.06M | 0.09% | 203 |
|
|
2015
Q2 | – | Sell |
-4,000
| Closed | -$498K | – | 779 |
|
|
2015
Q1 | $498K | Sell |
4,000
-16,000
| -80% | -$1.7M | 0.05% | 385 |
|
|
2014
Q4 | $1.81M | Sell |
20,000
-84,000
| -81% | -$6.99M | 0.21% | 98 |
|
|
2014
Q3 | $7.5M | Hold |
104,000
| – | – | 1.01% | 12 |
|
|
2014
Q2 | $6.47M | Buy |
104,000
+2,000
| +2% | +$121K | 0.9% | 13 |
|
|
2014
Q1 | $6.96M | Buy |
102,000
+4,600
| +5% | +$339K | 1.02% | 12 |
|
|
2013
Q4 | $6.85M | Sell |
97,400
-52,600
| -35% | -$3.57M | 1.04% | 12 |
|
|
2013
Q3 | $10.8M | Hold |
150,000
| – | – | 1.81% | 3 |
|
|
2013
Q2 | $8.36M | Buy |
+150,000
| New | +$9.35M | 1.53% | 5 |
|
Other funds holding BMRN
VPC
Shelton Capital Management's BMRN Position: Q2 2026 in Review
Shelton Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 2.9% in Q2 2026, selling an estimated $10.2K and leaving 6,219 shares worth $356K. The position accounts for 0.01% of the portfolio, ranked #477.
Shelton Capital Management first reported a position in BMRN in Q2 2013 and has held it in 37 quarters since. The position peaked at $10.8M in Q3 2013. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Shelton Capital Management held 6,219 shares of BioMarin Pharmaceuticals worth $356K as of Q2 2026.
- Shelton Capital Management sold 187 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $10.2K.
- BioMarin Pharmaceuticals made up 0.01% of Shelton Capital Management's portfolio in Q2 2026, its #477 holding.
- Shelton Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
- Shelton Capital Management's BioMarin Pharmaceuticals position peaked at $10.8M in Q3 2013.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Shelton Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.